{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:01:59Z","timestamp":1793754119349,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017160","name":"Beni Suef University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017160","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Autologous hematopoietic stem cell transplantation (AHSCT) is a valuable treatment option for several hematological malignancies, particularly in relapsed or refractory cases. Autologous hematopoietic stem cell transplantation (AHSCT) is effective in improving survival rates in selected patients, particularly those with aggressive lymphomas and multiple myeloma. Studies suggest AHSCT may outperform alternative therapies, but ongoing research is essential to refine patient selection. Many patients enjoy prolonged remission and improved quality of life, indicating the need for long-term follow-up to assess late effects and overall survival. This work aimed to establish meta-analysis to methodically evaluate the safety and effectiveness of autologous stem cell therapy (AHSCT) in the management of malignant lymphoma following high-dose chemotherapy and to produce reliable findings that may serve as a foundation for clinical application and reference.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic literature search was performed from February 2017 to August 2024, and\u00a0malignant lymphoma was identified as the study subjects' diagnosis. The experimental group was identified as AHSCT afterwards high-dose chemotherapy, while the control group underwent standard chemotherapy (with no restrictions on the chemotherapy regimen). The outcome indicators were progression-free survival (PFS), complete remission rate (complete response (CR)\u2009+\u2009partial response (PR)), and overall survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Fifteen literature pieces in all, consisting of 1229 subjects in the control group and 896 subjects in the experimental group, were included. Conventional chemotherapy (chemotherapy regimen not limited) was the intervention strategy used in the control group. The odds ratio (OR) was 2.23, with a 95% confidence interval (CI) of [1.54, 3.22], Z\u2009=\u20094.25; P\u2009&lt;\u20090.0001, indicating that the groups differed in overall survival and progression-free survival rates. Similarly, the progression-free survival rate was 2.70, with a 95% CI of 1.86\u20133.92, Z\u2009=\u20094.25; P\u2009&lt;\u20090.0001, and overall survival was 2.23.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients with malignant lymphoma who receive chemotherapy can substantially extend their overall survival and progression-free survival rates with AHSCT treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-01876-x","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:01:51Z","timestamp":1739455311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effectiveness and reliability of autologous hematopoietic stem cell transplantation following chemotherapy in managing malignant lymphoma: a meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Hend","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Shafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E. A.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"3","key":"1876_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms. Expert Rev Hematol. 2017;10(3):239\u201349.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"1876_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/bjh.15764","volume":"185","author":"MS Cairo","year":"2019","unstructured":"Cairo MS, Beishuizen A. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol. 2019;185(6):1021\u201342.","journal-title":"Br J Haematol"},{"issue":"2","key":"1876_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021;26(2):120\u201332.","journal-title":"Oncologist"},{"issue":"3","key":"1876_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295\u2013308.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1876_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DS Stroup","year":"2000","unstructured":"Stroup DS. Meta-analysis of observational studies in epidemiology. A proposal for reporting. J Am Med Assoc. 2000;283:2008\u201312.","journal-title":"J Am Med Assoc"},{"key":"1876_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, TAltman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557.","journal-title":"BMJ"},{"issue":"4","key":"1876_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):65\u201394.","journal-title":"Ann Intern Med"},{"key":"1876_CR8","unstructured":"Collaboration C. RoB. 2: A revised Cochrane risk-of-bias tool for randomized trials. Available at (Diakses 1 Juli 2022): bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials. 2020."},{"issue":"2","key":"1876_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216\u201321.","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"1876_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"1876_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/hon.2553","volume":"36","author":"A Jim\u00e9nez-Ubieto","year":"2018","unstructured":"Jim\u00e9nez-Ubieto A, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018;36(5):765\u201372.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1876_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24(6):1172\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1876_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823\u201333.","journal-title":"J Clin Oncol"},{"key":"1876_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12185-019-02791-y","volume":"111","author":"S Hagiwara","year":"2020","unstructured":"Hagiwara S, et al. Autologous peripheral blood stem cell transplantation for relapsed\/refractory HIV-associated lymphoma: a phase II clinical study. Int J Hematol. 2020;111:434\u20139.","journal-title":"Int J Hematol"},{"issue":"16","key":"1876_CR15","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/bloodadvances.2022007011","volume":"6","author":"P Lesueur","year":"2022","unstructured":"Lesueur P, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv. 2022;6(16):4807\u201315.","journal-title":"Blood Adv"},{"issue":"9","key":"1876_CR16","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3390\/cancers14092100","volume":"14","author":"S Seidel","year":"2022","unstructured":"Seidel S, et al. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in relapsed or refractory primary CNS lymphoma: a retrospective monocentric analysis of long-term outcome, prognostic factors, and toxicity. Cancers. 2022;14(9):2100.","journal-title":"Cancers"},{"key":"1876_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00066-021-01868-0","volume":"198","author":"B Metzner","year":"2022","unstructured":"Metzner B, et al. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease. Strahlenthera Onkol. 2022;198:39.","journal-title":"Strahlenthera Onkol"},{"issue":"8","key":"1876_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jtct.2023.05.011","volume":"29","author":"DJ Landsburg","year":"2023","unstructured":"Landsburg DJ, et al. Survival outcomes for patients with relapsed\/refractory aggressive B cell lymphomas following receipt of high-dose chemotherapy\/autologous stem transplantation and\/or chimeric antigen receptor-modified T cells. Transplant Cell Ther. 2023;29(8):495\u2013503.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"1876_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/cancers15030983","volume":"15","author":"K Kr\u00f6ger","year":"2023","unstructured":"Kr\u00f6ger K, et al. Long-term survival of patients with Mantle Cell Lymphoma after total body irradiation, high-dose chemotherapy and stem cell transplantation: a monocenter study. Cancers. 2023;15(3):983.","journal-title":"Cancers"},{"issue":"3","key":"1876_CR20","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","volume":"11","author":"E Schorb","year":"2024","unstructured":"Schorb E, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024;11(3):e196\u2013205.","journal-title":"Lancet Haematol"},{"issue":"10441","key":"1876_CR21","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. The Lancet. 2024;403(10441):2293\u2013306.","journal-title":"The Lancet"},{"key":"1876_CR22","doi-asserted-by":"crossref","unstructured":"Re A, et al. Autologous stem cell transplantation in HIV positive and HIV-negative patients with lymphoma: a propensity score matched comparative analysis. 2024.","DOI":"10.20944\/preprints202408.0537.v1"},{"issue":"3","key":"1876_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100018","volume":"1","author":"U D\u00fchrsen","year":"2024","unstructured":"D\u00fchrsen U, et al. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial. Blood Neoplasia. 2024;1(3): 100018.","journal-title":"Blood Neoplasia"},{"issue":"5","key":"1876_CR24","first-page":"192","volume":"33","author":"A Kallam","year":"2019","unstructured":"Kallam A, Vose JM. Hope after salvage therapy fails: novel agents for relapsed\/refractory hodgkin lymphoma. Oncology (Williston Park). 2019;33(5):192\u20138.","journal-title":"Oncology (Williston Park)"},{"key":"1876_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106689","volume":"110","author":"J Sapelli","year":"2021","unstructured":"Sapelli J, et al. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. Leuk Res. 2021;110: 106689.","journal-title":"Leuk Res"},{"issue":"1","key":"1876_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00432-021-03663-x","volume":"148","author":"MJ Steinhardt","year":"2022","unstructured":"Steinhardt MJ, et al. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC\/TT with BCNU\/aHSCT in primary aggressive lymphoma with CNS involvement. J Cancer Res Clin Oncol. 2022;148(1):205\u201314.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1876_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.21037\/tcr-22-595","volume":"11","author":"H Yu","year":"2022","unstructured":"Yu H, et al. Efficacy and safety of autologous hematopoietic stem cell transplantation in the treatment of malignant lymphoma after chemotherapy: a systematic review and meta-analysis. Transl Cancer Res. 2022;11(4):888.","journal-title":"Transl Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01876-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:01:59Z","timestamp":1739455319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01876-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}